| 51 | 3 | 33 |
| 下载次数 | 被引频次 | 阅读次数 |
报道1例绝经综合征合并子宫肌瘤、血压血脂异常患者的治疗过程。患者因“潮热，睡眠障碍”启用绝经激素治疗，治疗半年后至更年期医药联合门诊就诊，发现血压血脂异常。临床药师分析患者当前用药情况，结合患者特点，与医师共同制定个体化给药方案，并对患者进行用药教育与治疗效果监护。患者经治疗后绝经综合征症状控制良好。
Abstract：[1] DU L, XU B, HUANG C, et al. Menopausal symptoms and perimenopausal healthcare-seeking behavior in women aged 40-60 years:a community-based cross-sectional survey in Shanghai,China[J]. Int J Environ Res Public Health, 2020, 17(8):2640.
[2] DE VILLIERS T J, HALL J E, PINKERTON J V, et al. Revised global consensus statement on menopausal hormone therapy[J].Maturitas, 2016, 91:153.
[3] MORO E, DEGLI ESPOSTI E, BORGHESE G, et al. The impact of hormonal replacement treatment in postmenopausal women with uterine fibroids:a state-of-the-art review of the literature[J].Medicina(Kaunas), 2019, 55(9):549.
[4] BRENNAN A, REES M. Menopausal hormone therapy in women with benign gynaecological conditions and cancer[J]. Best Pract Res Clin Endocrinol Metab, 2021, 35(6):101575.
[5] The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society[J]. Menopause, 2017, 24(7):728.
[6] PRENTICE R L, ARAGAKI A K, CHLEBOWSKI R T, et al. Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50-59 years of age[J].Am J Epidemiol, 2021, 190(3):365.
[7] IORGA A, CUNNINGHAM C M, MOAZENI S, et al. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy[J]. Biol Sex Differ, 2017, 8(1):33.
[8] NAFTOLIN F, FRIEDENTHAL J, NACHTIGALL R, et al.Cardiovascular health and the menopausal woman:the role of estrogen and when to begin and end hormone treatment[J].F1000Res, 2019, 8:1576.
[9] NEWSON L. Menopause and cardiovascular disease[J]. Post Reprod Health, 2018, 24(1):44.
[10]中国心血管病风险评估和管理指南编写联合委员会,顾东风.中国心血管病风险评估和管理指南[J].中华预防医学杂志, 2019,53(1):13.
[11] KAPOOR E, COLLAZO-CLAVELL M L, FAUBION S S. Weight gain in women at midlife:a concise review of the pathophysiology and strategies for management[J]. Mayo Clin Proc, 2017, 92(10):1552.
[12] MADIKA A L, MACDONALD C J, FOURNIER A, et al.Menopausal hormone therapy and risk of incident hypertension:role of the route of estrogen administration and progestogens in the E3N cohort[J]. Menopause, 2021, 28(11):1204.
[13] WILD R A, LARSON J C, CRANDALL C J, et al. Hormone therapy formulation, dose, route of delivery, and risk of hypertension:findings from the Women’s Health Initiative Observational Study(WHI-OS)[J]. Menopause, 2021, 28(10):1108.
[14] SWICA Y, WARREN M P, MANSON J E, et al. Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women’s Health Initiative hormone therapy trials[J]. Menopause, 2018, 25(7):753.
[15] BIRKH?USER M. Menopausal Hormone Therapy in women with other underlying diseases:how to proceed?[J]. Ther Umsch,2021, 78(8):483.
[16] KAPOOR E, KLING J M, LOBO A S, et al. Menopausal hormone therapy in women with medical conditions[J]. Best Pract Res Clin Endocrinol Metab, 2021, 35(6):101578.
[17] ANAGNOSTIS P, BITZER J, CANO A, et al. Menopause symptom management in women with dyslipidemias:an EMAS clinical guide[J]. Maturitas, 2020, 135:82.
[18] ULIN M, ALI M, CHAUDHRY Z T, et al. Uterine fibroids in menopause and perimenopause[J]. Menopause, 2020, 27(2):238.
[19] GIANNUBILO S R, CIAVATTINI A, PETRAGLIA F, et al.Management of fibroids in perimenopausal women[J]. Curr Opin Obstet Gynecol, 2015, 27(6):416.
[20] SRINIVASAN V, MARTENS M G. Hormone therapy in menopausal women with fibroids:is it safe?[J]. Menopause, 2018, 25(8):930.
[21] KIM H K, JEON S H, RYU K J, et al. Comparison of the efficacy of tibolone and transdermal estrogen in treating menopausal symptoms in postmenopausal women[J]. J Menopausal Med, 2019, 25(3):123.
[22] FORMOSO G, PERRONE E, MALTONI S, et al. Short-term and long-term effects of tibolone in postmenopausal women[J].Cochrane Database Syst Rev, 2016, 10(10):CD008536.
[23] YUAN Q, SANTOS H O, ALSHAHRANI M S, et al. Does tibolone treatment have favorable effects on obesity, blood pressure, and inflammation? A meta-analysis of randomized controlled trials[J].Steroids, 2022, 178:108966.
[24] ISSA Z, SEELY E W, RAHME M, et al. Effects of hormone therapy on blood pressure[J]. Menopause, 2015, 22(4):456.
[25] LV C Y, ZHANG W C, TAN X, et al. The effect of tibolone treatment on lipid profile in women:a systematic review and doseresponse meta-analysis of randomized controlled trials[J].Pharmacol Res, 2021, 169:105612.
[26] GENAZZANI A R, MONTELEONE P, GIANNINI A, et al.Pharmacotherapeutic options for the treatment of menopausal symptoms[J]. Expert Opin Pharmacother, 2021, 22(13):1773.
[27]中国医师协会全科医师分会,北京妇产学会社区与基层分会,孙艳格,等.更年期妇女健康管理专家共识(基层版)[J].中国全科医学, 2021(11):1317.
[28] TIMMER C J, HUISMAN J A M. Effect of a standardized meal on the bioavailability of a single oral dose of tibolone 2.5 Mg in healthy postmenopausal women[J]. Pharmacotherapy, 2002,22(3):310.
[29]中华医学会妇产科学分会绝经学组.中国绝经管理与绝经激素治疗指南(2018)[J].协和医学杂志, 2018, 9(6):19.
[30] VUKADINOVI?D, SCHOLZ S S, MESSERLI F H, et al.Peripheral edema and headache associated with amlodipine treatment:a meta-analysis of randomized, placebo-controlled trials[J]. J Hypertens, 2019, 37(10):2093.
基本信息:
DOI：10.19577/j.1007-4406.2023.06.013
中图分类号:R711.75;R737.33;R589.2
引用信息:
[1]周婷,鲍红荣,詹侠,等.临床药师参与1例绝经综合征伴子宫肌瘤、血压血脂异常的治疗实践[J].中国临床药学杂志,2023,32(06):462-466.DOI:10.19577/j.1007-4406.2023.06.013.
基金信息:
杭州市临安区第一人民医院院级课题科研项目（编号LY202126）
2023-06-25
2023-06-25